{"id":"NCT05144945","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Study Describing the Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) Versus a Licensed Quadrivalent-inactivated Influenza Vaccine (IIV4) (Fluarix® Quadrivalent) in Participants 18 Years of Age and Older in South Korea","officialTitle":"A Phase III Randomized, Modified Double-blind, Active-controlled, Multi-center Study to Describe the Immunogenicity and Safety of the Quadrivalent Recombinant Influenza Vaccine (RIV4) Versus a Quadrivalent-inactivated Influenza Vaccine (IIV4) (Fluarix® Quadrivalent) in Participants 18 Years of Age and Older in South Korea","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-12-07","primaryCompletion":"2022-09-01","completion":"2022-09-01","firstPosted":"2021-12-06","resultsPosted":"2023-09-29","lastUpdate":"2025-09-11"},"enrollment":301,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Influenza (Healthy Volunteers)"],"interventions":[{"type":"BIOLOGICAL","name":"Quadrivalent Recombinant Influenza Vaccine (RIV4)","otherNames":[]},{"type":"BIOLOGICAL","name":"Quadrivalent inactivated influenza vaccine (IIV4)","otherNames":["Fluarix®"]}],"arms":[{"label":"Group 1: Quadrivalent Recombinant Influenza Vaccine (RIV4)","type":"EXPERIMENTAL"},{"label":"Group 2: Quadrivalent-inactivated Influenza Vaccine (IIV4)","type":"ACTIVE_COMPARATOR"}],"summary":"* To describe the immune response induced by quadrivalent recombinant influenza vaccine (RIV4) and Quadrivalent-inactivated Influenza Vaccine (IIV4) in 18-49 and greater than or equal to (\\>=) 50 years of age participants by hemagglutination inhibition (HAI) measurement method.\n* To describe the safety profile of all participants in RIV4 and IIV4 groups.","primaryOutcome":{"measure":"Geometric Mean Titers (GMTs) of Influenza Vaccine Antibodies at Day 1- Per Protocol Analysis Set (PPAS)","timeFrame":"Day 1 (pre-vaccination)","effectByArm":[{"arm":"Group 1: Quadrivalent Recombinant Influenza Vaccine (RIV4)","deltaMin":30.8,"sd":null},{"arm":"Group 2: Quadrivalent-inactivated Influenza Vaccine (IIV4)","deltaMin":38.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":14},"locations":{"siteCount":3,"countries":["South Korea"]},"refs":{"pmids":["40752250"],"seeAlso":["https://www.trialsummaries.com/Study/StudyDetails?id=25369&tenant=MT_SNY_9011"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":149},"commonTop":["Injection Site Pain","Myalgia","Malaise","Fatigue","Headache"]}}